{"id":"NCT02161562","sponsor":"Novartis Pharmaceuticals","briefTitle":"OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients","officialTitle":"OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in CSU Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-08-01","primaryCompletion":"2016-11-03","completion":"2016-11-03","firstPosted":"2014-06-11","resultsPosted":"2018-08-08","lastUpdate":"2018-09-13"},"enrollment":314,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Spontaneous Urticaria"],"interventions":[{"type":"DRUG","name":"omalizumab","otherNames":[]},{"type":"DRUG","name":"omalizumab","otherNames":[]}],"arms":[{"label":"omalizumab 150mg","type":"EXPERIMENTAL"},{"label":"omalizumab 300mg","type":"EXPERIMENTAL"}],"summary":"This trial assessed the efficacy of optimized re-treatment therapy with omalizumab (150mg or 300mg) after relapse, in participants with Chronic Spontaneous Urticaria who were clinically well-controlled following their first course of treatment with omalizumab (150mg or 300mg). The study also assessed the benefit of uptitrating to 300mg dose in participants who were not well-controlled following their initial course of treatment with omalizumab 150mg, as well as the benefit of treatment extension of those patients who were not well-controlled following their initial course of treatment with omalizumab 300mg.","primaryOutcome":{"measure":"Number of Participants Who Were Clinically Well-controlled (UAS7<=6) After the Initial Dosing Period, Relapsed (UAS7>=16) When Treatment Was Discontinued, and Who Achieved a UAS7 Score <=6 at the End of the Second Dosing Period (Retreatment A2 and B2)","timeFrame":"Last 7 days of second dosing period, 44 weeks","effectByArm":[{"arm":"All Retreatment (A2&B2)","deltaMin":43,"sd":null},{"arm":"Retreatment (A2)","deltaMin":10,"sd":null},{"arm":"Retreatment (B2)","deltaMin":33,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":35,"countries":["Argentina","Brazil","Canada","Chile","Dominican Republic","Guatemala","Mexico","Panama"]},"refs":{"pmids":["32272284"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":178},"commonTop":["Nasopharyngitis","Headache","Upper respiratory tract infection","Urticaria","Fatigue"]}}